PT  - JOURNAL ARTICLE
AU  - Nasiri, Mohammad Javad
AU  - Haddadi, Sara
AU  - Tahvildari, Azin
AU  - Farsi, Yeganeh
AU  - Arbabi, Mahta
AU  - Hasanzadeh, Saba
AU  - Jamshidi, Parnian
AU  - Murthi, Mukunthan
AU  - Mirsaeidi, Mehdi S.
TI  - COVID-19 clinical characteristics, and sex-specific risk of mortality: Systematic Review and Meta-analysis
AID  - 10.1101/2020.03.24.20042903
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.24.20042903
4099  - http://medrxiv.org/content/early/2020/03/26/2020.03.24.20042903.short
4100  - http://medrxiv.org/content/early/2020/03/26/2020.03.24.20042903.full
AB  - Objectives The rapidly evolving coronavirus disease 2019 (COVID-19), was declared a pandemic by the World Health Organization on March 11, 2020. It was first detected in the city of Wuhan in China and has spread globally resulting in substantial health and economic crisis in many countries. Observational studies have partially identified the different aspects of this disease. Up to this date, no comprehensive systematic review for the clinical, laboratory, epidemiologic and mortality findings has been published. We conducted this systematic review and meta-analysis for a better understanding of COVID-19.Methods We reviewed the scientific literature published from January 1, 2019 to March 3, 2020. Statistical analyses were performed with STATA (version 14, IC; Stata Corporation, College Station, TX, USA). The pooled frequency with 95% confidence intervals (CI) was assessed using random effect model. Publication bias was assessed and p <0.05 was considered a statistically significant publication bias.Results Out of 1102 studies, 32 satisfied the inclusion criteria. A total of 4789 patients with a mean age of 49 years were evaluated. Fever (83.0%, CI 77.5 to 87.6), cough (65.2%, CI 58.6 to 71.2) and myalgia/fatigue (34.7, CI 26.0 to 44.4) were the most common symptoms. The most prevalent comorbidities were hypertension (18.5 %, CI 12.7 to 24.4) and Cardiovascular disease (14.9 %, CI 6.0 to 23.8). Among the laboratory abnormalities, elevated C-Reactive Protein (CRP) (72.0% (CI 54.3 to 84.6) and lymphopenia (50.1%, CI 38.0 to 62.4) were the most common findings. Bilateral ground-glass opacities (66.0%, CI 51.1 to 78.0) was the most common CT-Scan presentation. Pooled mortality rate was 6.6%, with males having significantly higher mortality compared to females (OR 3.4; 95% CI 1.2 to 9.1, P = 0.01).Conclusion COVID-19 commonly presented with a progressive course of cough and fever with more than half of hospitalized patients showing leukopenia or a high CRP on their laboratory findings. Mortality associated with COVID19 was higher than that reported in studies in China with Males having a 3-fold higher risk of mortality in COVID19 compared to females.What is already known in this topicCOVID-19 was declared a pandemic by the World Health Organization on March 11, 2020.Many observational studies have separately dealt with different clinical and epidemiologic features of this new and rapidly evolving disease.Very few systematic reviews about COVID-19 have been done and there was still a need for a systematic review and meta-analysis related to the clinical findings and the mortality of the disease in order to have a better understanding of COVID-19.Previous reports have indicated that older age and presence of multiple comorbidities are associated with increased mortality.What this study addsThe mortality rate in our study for hospitalized COVID-19 patients was 6.6% and males had around 3-fold higher risk of mortality compared to females (OR 3.4; 95% CI 1.2-9.1, P = 0.01).These findings could indicate the need for more aggressive treatment of COVID-19 in males.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAuthors can confirm that all relevant data are included in the article and/or its supplementary information files